The pan-PPAR agonist lanifibranor improves cardiometabolic health in patients with metabolic dysfunction-associated steatohepatitis
Source
Nature communications - ISSN 2041-1723-15:1 (2024) p. 1-13
Metabolic dysfunction-associated steatotic liver disease is associated with worse time in ranges in type 1 diabetes
Source
Diabetes, obesity & metabolism - ISSN 1462-8902- (2024) p.
MASLD/MASH and type 2 diabetes : two sides of the same coin? From single PPAR to pan-PPAR agonists
Source
Diabetes research and clinical practice - ISSN 0168-8227-212 (2024) p. 1-11
Hepatic venous pressure gradient predicts risk of hepatic decompensation and liver-related mortality in patients with MASLD
Source
Journal of hepatology - ISSN 0168-8278- (2024) p.
Emerging role of ferroptosis in metabolic dysfunction-associated steatotic liver disease : revisiting hepatic lipid peroxidation
Source
EBioMedicine - ISSN 2352-3964-102 (2024) p. 1-18